Drug Channels

AUGUST 8, 2023

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Recently, a bipartisan group of six U.S. Click here to read the full letter. I submitted a 14-page letter, which you can read below.

Pharmacy 96

Pharmacy Hospitals Drugs Pharmaceuticals 96

Drug Channels

APRIL 8, 2022

Michael discusses patient support challenges that are unique to specialty-lite pharmaceuticals. He goes on to describe four new categories of patient solutions and pharmacy models specific to this growing market segment. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. Read on for Michael’s insights.

Specialty Pharmacies 96

Specialty Pharmacies Pharmacy Production Pharmaceuticals 96

Drug Channels

MAY 24, 2023

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. to 1:30 p.m. Click here to learn more and register.

Pharmacy 98

Pharmacy Pharmaceuticals Marketing Drugs 98

Drug Channels

MAY 21, 2024

WHAT YOU WILL LEARN The federal 340B Drug Pricing Program continues to grow much more quickly than the overall pharmaceutical market. DCI estimates that 340B discounts equated to more than 17% of total value of gross-to-net reductions for brand-name pharmaceuticals. Pharmacies and Pharmacy Benefit Managers.

Pharmacy 52

Pharmacy Drugs Pharmaceuticals Marketing 52

Drug Channels

JUNE 1, 2020

Like many of you, I was disappointed that Asembia had to cancel its 2020 Specialty Pharmacy Summit. You can view them for FREE if your registration to the 2020 Specialty Pharmacy Summit was transferred to the 2021 Summit. Click here to register for access to Asembia’s Specialty Pharmacy Summit Virtual Experience.

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Pharmaceuticals Marketing 40

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business. and Section 6.4.3.

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Drug Channels

JULY 29, 2022

Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. healthcare spending. spending on healthcare.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

Drug Channels

SEPTEMBER 12, 2023

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. As always, we have updated all market and industry data with the most current information available. Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals 52

Pharmaceuticals Pharmacy Biosimilars Licensing 52

Drug Channels

OCTOBER 23, 2023

A program driven by market dynamics and led by champions of channel strategy, join now to master the complexities of pharmacy and distribution models to accelerate market access –It's all happening December 11-13, 2023. Why should you attend this pivotal event? How is health policy affecting the distribution channel?

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. examines how the Inflation Reduction Act could ultimately impact pharmaceutical wholesalers’ customers and business outlook.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

Drug Channels

APRIL 12, 2022

As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. What’s more, taxpayers—via Medicare and Medicaid—will continue to crowd out the private insurance market. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. to 1:30 p.m.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. reviews AmerisourceBergen’s entry into the European distribution market. (We Copyright © 2006-2021 Pembroke Consulting, Inc.

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 52

Drug Channels

SEPTEMBER 21, 2020

This important event convenes key stakeholders including manufacturers, specialty pharmacies, hubs, payers, PBMs, physicians and more to explore strategies for developing and integrating hub programs and other patient-centric services to ensure product access and optimal reimbursement. Copyright © 2006-2020 Pembroke Consulting, Inc.

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

SEPTEMBER 9, 2021

In Cardinal’s 2021 fiscal year, CVS purchased more than $42 billion in pharmaceuticals from the wholesaler—about double the figure from 10 years ago. The two wholesalers sell more than $90 billion in pharmaceuticals to CVS Health—making it the largest U.S. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. to 1:30 p.m.

Pharmaceuticals 98

Pharmaceuticals Marketing Drugs Pharmacy 98

Drug Channels

OCTOBER 13, 2020

I am pleased to announce our new 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. The 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is the only resource of its kind available anywhere. healthcare system.

Pharmaceuticals 52

Pharmaceuticals Licensing Licensing Pharmacy 52

Drug Channels

NOVEMBER 8, 2020

Copyright © 2006-2020 Pembroke Consulting, Inc. Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more! Other restrictions may apply. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Pharmaceuticals 52

Drug Channels

OCTOBER 19, 2020

Channel Strategy for First Medical Product – A Look at Channel Considerations for Pharmacy vs. Medical Plus – Tailored Track Options Based on Company Size : Emerging/Small Companies – Infrastructure Set-Up, License Procurement and 3PL Contracting Mid-Large Companies – How Do I Think About My Portfolio Differently Based on Product Type?

Specialty Pharmacies 52

Specialty Pharmacies Science Pharmacy Licensing 52

Drug Channels

DECEMBER 1, 2020

During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Pharmacy and healthcare provider markets experienced unprecedented volatility. Pharmaceutical wholesalers have maintained shipments and operational capacity. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Vaccine Drugs Pharmaceuticals 52

Drug Channels

MAY 3, 2021

Copyright © 2006-2021 Pembroke Consulting, Inc. and more! * Expires 6/25/20210; applies to standard rate only and may not be combined or applied to existing registrations; other restrictions may apply. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Pharmacy 40

Pharmacy Government Pharmaceuticals Science 40

Drug Channels

MAY 22, 2023

WHAT YOU WILL LEARN As expensive specialty therapies come to dominate drug spending, pharmaceutical manufacturers are paying a growing share of patents’ out-of-pocket costs for these prescriptions. Pharmacies and Pharmacy Benefit Managers. Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Pharmacy 97

Pharmacy Drugs Marketing Pharmaceuticals 97

Drug Channels

MARCH 26, 2021

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. For your reference, I also include links to published comments from the American Hospital Association and the Pharmaceutical Research and Manufacturers of America. I shared my $0.02

Pharmacy 52

Pharmacy Hospitals Pharmaceuticals Marketing 52

Drug Channels

NOVEMBER 4, 2020

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. For your reference, I also include links to published comments from the American Hospital Association and the Pharmaceutical Research and Manufacturers of America. I shared my $0.02

Pharmacy 52

Pharmacy Hospitals Pharmaceuticals Marketing 52

Drug & Device Law

JUNE 2, 2022

Even with some attempt to “stay in our lane,” we can see significant impacts on the legal framework in which a number of medical product manufacturers, to say nothing of distributors, pharmacies, and healthcare providers, operate. This is not a matter of us injecting our personal and political views into areas we do not belong. 472 (2013).

FDA Approval 127

FDA Approval Pharmacy FDA Drugs 127

Drug & Device Law

FEBRUARY 20, 2023

In product liability litigation generally, plaintiffs have been allowed to invent all kinds of “alternative” designs as long as some “expert” opines that the design (even if never before marketed) is “feasible.” 2006), app. 2006), app. For physicians to prescribe such a safer drug, it must reach the market. 2d 506 (N.Y.

FDA 59

FDA FDA Approval Testimonials Vaccine 59